Sumitomo Pharma

4506.T

Osaka, Japan· Est. 1892

sumitomo-pharma.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4506.T · Stock Price

JPY 1,613+649 (+67.32%)

Market Cap: $4.1B

Historical price data

Market Cap: $4.1BPipeline: 200 drugs (109 Phase 3)Patents: 20Founded: 1892Employees: 5000-10000HQ: Osaka, Japan

Overview

Sumitomo Pharma's mission is to translate cutting-edge science into innovative therapies that address significant unmet medical needs, particularly in psychiatry and oncology. The company has achieved global recognition through its commercialized products like Latuda® (lurasidone) and is advancing a robust pipeline of next-generation modalities. Its strategy hinges on a balanced portfolio, combining revenue-generating assets with high-risk, high-reward R&D in gene therapy and radiopharmaceuticals, supported by strategic global partnerships and internal discovery capabilities.

PsychiatryOncologyRegenerative Medicine

Technology Platform

A multi-modal R&D engine encompassing small molecules, targeted protein degraders, gene therapy vectors (via partnership), targeted radioligand therapies (TRT), and cell-based regenerative medicines.

Pipeline

200

200 drugs in pipeline109 in Phase 3

Drug	Indication	Stage
Eslicarbazepine acetate	Epilepsy	Phase 3
Eszopiclone + placebo	Insomnia	Phase 3
APL-130277 + subcutaneous apomorphine	Motor OFF Episodes Associated With Parkinson's Disease	Phase 3
Lurasidone	Schizophrenia	Phase 3
DSP-7888 Dosing Emulsion + Bevacizumab	Glioblastoma	Phase 3

FDA Approved Drugs

MYFEMBREENDAMay 26, 2021

GEMTESANDADec 23, 2020

ORGOVYXNDADec 18, 2020

Opportunities

Near-term launch of Ansofaxine in the massive US MDD market and mid-term data from novel oncology platforms (protein degradation, radioligand therapy) represent significant value inflection points.

The company's diversified modality approach could yield breakthrough therapies in areas of high unmet need.

Risk Factors

High clinical and regulatory risk for novel platform assets; intense competition and pricing pressure in core psychiatry and oncology markets; execution risk in integrating global operations and advancing complex therapies.

Competitive Landscape

Faces formidable competition: in psychiatry from J&J, Otsuka, and generics; in novel oncology modalities from leaders like Novartis (TRT) and Arvinas (protein degradation). Success requires demonstrating best-in-class efficacy and superior commercial execution.